Drug Trial Radar · NCT07783542
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Aug 21, 2026
Primary completion
Oct 2028
Study completion Sep 2029
Sponsor
- Lead sponsor
- Oruka Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
ORKA-002Drug
ORKA-002 administered by subcutaneous (SC) injection
PlaceboOther
Placebo administered by subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving HiSCR75 at Week 16Time frame: Week 16
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
Oruka Therapeutics Investigative Site
Birmingham, Alabama · Recruiting
Oruka Therapeutics Investigative Site
Fountain Valley, California · Recruiting
Oruka Therapeutics Investigative Site
Los Angeles, California · Recruiting
Oruka Therapeutics Investigative Site
Cromwell, Connecticut · Recruiting
Oruka Therapeutics Investigative Site
Sandy Springs, Georgia · Recruiting
Oruka Therapeutics Investigative Site
Chicago, Illinois · Recruiting
Oruka Therapeutics Investigative Site
Plainfield, Indiana · Recruiting
Oruka Therapeutics Investigative Site
Baton Rouge, Louisiana · Recruiting
Oruka Therapeutics Investigative Site
New Orleans, Louisiana · Recruiting
Oruka Therapeutics Investigative Site
Canton, Michigan · Recruiting
Oruka Therapeutics Investigative Site
New Brighton, Minnesota · Recruiting
Oruka Therapeutics Investigative Site
St Louis, Missouri · Recruiting
Oruka Therapeutics Investigative Site
Omaha, Nebraska · Recruiting
Oruka Therapeutics Investigative Site
New York, New York · Recruiting
Oruka Therapeutics Investigative Site
Chapel Hill, North Carolina · Recruiting
Oruka Therapeutics Investigative Site
Portland, Oregon · Recruiting
Oruka Therapeutics Investigative Site
Smyrna, Tennessee · Recruiting
Oruka Therapeutics Investigative Site
Dallas, Texas · Recruiting
Oruka Therapeutics Investigative Site
Missouri City, Texas · Recruiting
Oruka Therapeutics Investigative Site
San Antonio, Texas · Recruiting
Oruka Therapeutics Investigative Site
Surrey, British Colombia, Canada · Recruiting
Oruka Therapeutics Investigative Site
Barrie, Ontario, Canada · Recruiting
Oruka Therapeutics Investigative Site
London, Ontario, Canada · Recruiting
Oruka Therapeutics Investigative Site
Peterborough, Ontario, Canada · Recruiting
Oruka Therapeutics Investigative Site
Waterloo, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.